Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1920 ARTÍCULOS , VIENDO DEL 1381 AL 1395

Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial

Wagemann O, Liu H, Wang G, Shi X, Bittner T, Scelsi MA, Farlow MR, Clifford DB, Supnet-Bell C, Santacruz AM, Aschenbrenner AJ, Hassenstab JJ, Benzinger TLS, Gordon BA, Coalier KA, Cruchaga C, Ibanez L, Perrin RJ, Xiong C, Li Y, Morris JC, Lah JJ, Berman SB, Roberson ED, van Dyck CH, Galasko D, Gauthier S, Hsiung GR, Brooks WS, Pariente J, Mummery CJ, Day GS, Ringman JM, Mendez PC, St George-Hyslop P, Fox NC, Suzuki K, Okhravi HR, Chhatwal J, Levin J, Jucker M, Sims JR, Holdridge KC, Proctor NK, Yaari R, Andersen SW, Mancini M, Llibre-Guerra J, Bateman RJ, McDade E; Dominantly Inherited Alzheimer Network–Trials Unit.

JAMA Neurol. 2024 Jun 1;81(6):582-593. doi: 10.1001/jamaneurol.2024.0991.

Language and Meaning: Asymptomatic Alzheimer's Disease in the Clinic and Society

Gale SA.

J Alzheimers Dis. 2024;99(2):489-492. doi: 10.3233/JAD-240195.

Multiomics Blood-Based Biomarkers Predict Alzheimer's Predementia with High Specificity in a Multicentric Cohort Study

Souchet B, Michaïl A, Heuillet M, Dupuy-Gayral A, Haudebourg E, Pech C, Berthemy AA, Autelitano F, Billoir B, Domoto-Reilly K, Fowler C, Grabowski T, Jayadev S, Masters CL, Braudeau J.

J Prev Alzheimers Dis. 2024;11(3):567-581. doi: 10.14283/jpad.2024.34.

Polygenic Risk Score Reveals Genetic Heterogeneity of Alzheimer's Disease between the Chinese and European Populations

Li F, Xie S, Cui J, Li Y, Li T, Wang Y, Jia J.

J Prev Alzheimers Dis. 2024;11(3):701-709. doi: 10.14283/jpad.2024.29.

Association of Vascular Endothelial Growth Factor Levels with Risk of Alzheimer's Disease: A Systematic Review and Meta-Analysis

Zakariaee SS, Naderi N, Azizi E.

J Prev Alzheimers Dis. 2024;11(3):721-729. doi: 10.14283/jpad.2024.18.

Towards early diagnosis of Alzheimer's disease: advances in immune-related blood biomarkers and computational approaches

Krix S, Wilczynski E, Falgàs N, Sánchez-Valle R, Yoles E, Nevo U, Baruch K, Fröhlich H.

Front Immunol. 2024 Apr 23;15:1343900. doi: 10.3389/fimmu.2024.1343900. eCollection 2024.

Assessment of the Correlation and Diagnostic Accuracy between Cerebrospinal Fluid and Plasma Alzheimer's Disease Biomarkers: A Comparison of the Lumipulse and Simoa Platforms

Dakterzada F, Cipriani R, López-Ortega R, Arias A, Riba-Llena I, Ruiz-Julián M, Huerto R, Tahan N, Matute C, Capetillo-Zarate E, Piñol-Ripoll G.

Int J Mol Sci. 2024 Apr 23;25(9):4594. doi: 10.3390/ijms25094594.

Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease

Pradeepkiran JA, Baig J, Islam MA, Kshirsagar S, Reddy PH.

Aging Dis. 2024 Apr 24;16(2):658-682. doi: 10.14336/AD.2024.0286.

Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting

Zeng X, Chen Y, Sehrawat A, Lee J, Lafferty TK, Kofler J, Berman SB, Sweet RA, Tudorascu DL, Klunk WE, Ikonomovic MD, Pfister A, Zetterberg H, Snitz BE, Cohen AD, Villemagne VL, Pascoal TA, Kamboh MI, Lopez OI, Blennow K, Karikari TK.

Mol Neurodegener. 2024 May 15;19(1):40. doi: 10.1186/s13024-024-00711-1.

Relationship Between Cerebrospinal Fluid Alzheimer's Disease Biomarker Values Measured via Lumipulse Assays and Conventional ELISA: Single-Center Experience and Systematic Review

Kurihara M, Kondo S, Ohse K, Nojima H, Kikkawa-Saito E, Iwata A.

J Alzheimers Dis. 2024;99(3):1077-1092. doi: 10.3233/JAD-240185.

p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial

Shanks HRC, Chen K, Reiman EM, Blennow K, Cummings JL, Massa SM, Longo FM, Börjesson-Hanson A, Windisch M, Schmitz TW.

Nat Med. 2024 Jun;30(6):1761-1770. doi: 10.1038/s41591-024-02977-w. Epub 2024 May 17.

Progress on early diagnosing Alzheimer's disease

Chen Y, Al-Nusaif M, Li S, Tan X, Yang H, Cai H, Le W.

Front Med. 2024 Jun;18(3):446-464. doi: 10.1007/s11684-023-1047-1. Epub 2024 May 21.

Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease

Penny LK, Lofthouse R, Arastoo M, Porter A, Palliyil S, Harrington CR, Wischik CM.

Transl Neurodegener. 2024 May 21;13(1):25. doi: 10.1186/s40035-024-00417-w.

Predicting Driving Cessation Among Cognitively Normal Older Drivers: The Role of Alzheimer Disease Biomarkers and Clinical Assessments

Babulal GM, Chen L, Murphy SA, Carr DB, Morris JC.

Neurology. 2024 Jun 25;102(12):e209426. doi: 10.1212/WNL.0000000000209426. Epub 2024 Apr 15.

Predicting Driving Cessation in Alzheimer Disease: Performance Beats Biomarkers

Dubinsky RM, Stein AC.

Neurology. 2024 Jun 25;102(12):e209523. doi: 10.1212/WNL.0000000000209523. Epub 2024 Apr 15.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias